GeNeuro is a Phase2 clinical-stage company that develops antibodies to neutralize patient-produced pathogenic proteins that fuel a great number of neurodegenerative and autoimmune diseases. GeNeuro leverages this approach against diseases ranging from multiple sclerosis to post-COVID syndrome.

Products, services, technology

GeNeuro's temelimab, a humanized monoclonal antibody targeting HERV-W Env, has shown a coherent impact across all key markers associated with disease progression in a 200-patient 2y study in MS. Its final Phase2, focusing on disability progression markers, will readout in March 2022.

Facts & figures
  • Type of organization
    Public company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in